Trialo
Trialo provides fast, evidence-based insights to speed drug development. It uses AI to extract and analyze efficacy endpoints from regulatory submissions, scientific literature, company announcements, and public documents. Built on proprietary AI architecture and trial endpoint recognition technology, Trialo offers tools like DiseaseXplorer for indication-centric analytics, Smart Endpoint Analytics for standardized efficacy comparisons, AI Research Assistant for instant, evidence-based insights, and Source Document Verification for regulatory-grade validation. It is a B2B SaaS platform serving pharmaceutical companies, investors, and research organizations, integrating structured data across regulatory and scientific sources. The platform enables cross-indication efficacy comparisons, faster trial design, and market opportunities by delivering regulatory-grade evidence summaries in minutes rather than months.
Trialo
Trialo provides fast, evidence-based insights to speed drug development. It uses AI to extract and analyze efficacy endpoints from regulatory submissions, scientific literature, company announcements, and public documents. Built on proprietary AI architecture and trial endpoint recognition technology, Trialo offers tools like DiseaseXplorer for indication-centric analytics, Smart Endpoint Analytics for standardized efficacy comparisons, AI Research Assistant for instant, evidence-based insights, and Source Document Verification for regulatory-grade validation. It is a B2B SaaS platform serving pharmaceutical companies, investors, and research organizations, integrating structured data across regulatory and scientific sources. The platform enables cross-indication efficacy comparisons, faster trial design, and market opportunities by delivering regulatory-grade evidence summaries in minutes rather than months.